中藥股繼續走強:萊茵生物和精華製藥漲停
格隆匯1月14日丨萊茵生物、精華製藥漲停,佐力藥業和眾生藥業漲超7%,以嶺藥業漲超6%,健民集團漲超5%,太極集團、漢森製藥、益佰製藥、紅日藥業、太安堂漲超4%,江中藥業、九芝堂、羚鋭製藥、馬應龍、太龍藥業漲超3%。消息面上,農業農村部近日印發《“十四五”全國種植業發展規劃》指出,到2025年,全國中藥材面積穩定在4500萬畝左右,道地藥材面積佔總面積50%以上。另外,國家藥監局召開推動東北全面振興座談會,貫徹落實《東北全面振興“十四五”實施方案》《國家藥監局支持東北全面振興的若干措施》等文件強調,要支持中醫藥傳承創新發展,打造東北道地藥材品牌,加強中藥質量安全監管。要持續推進“放管服”改革,激發市場主體活力,培育醫藥產業區域品牌。要全面加強藥品監管能力建設,着力強基礎、補短板、破瓶頸、促提升,提升藥品監管現代化水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.